Robotic Radiotherapy Market by Product Type (Gantry-Based Systems, Robotic Arm-Based Systems), Component (Hardware, Services, Software), Treatment Application, Modality, End User - Global Forecast 2026-2032
Description
The Robotic Radiotherapy Market was valued at USD 1.48 billion in 2025 and is projected to grow to USD 1.64 billion in 2026, with a CAGR of 11.08%, reaching USD 3.09 billion by 2032.
Framing the strategic and clinical rationale for robotic radiotherapy adoption by synthesizing precision performance, workflow integration, and stakeholder investment priorities
Robotic radiotherapy represents a convergence of precision engineering, advanced imaging, and adaptive clinical workflows that is reshaping radiotherapeutic practice. This report’s introduction frames the technology’s clinical imperatives, from submillimeter targeting and motion compensation to reduced treatment margins that preserve healthy tissue. It also situates robotic radiotherapy within broader oncology care trajectories, where multidisciplinary coordination, patient throughput pressures, and emerging reimbursement paradigms influence adoption decisions.
Transitioning from clinical potential to operational reality requires clarity on technology differentiation, capital and operational expenditure trade-offs, and the interoperability requirements that health systems prioritize. The introduction therefore summarizes the core technical capabilities that matter to radiation oncologists and medical physicists, outlines how device ecosystems integrate with oncology information systems and imaging modalities, and highlights adoption catalysts such as evidence demonstrating improved toxicity profiles or workflow efficiencies. Taken together, this orientation establishes the analytical lens used throughout the report to evaluate strategic choices facing manufacturers, providers, and payers.
Identifying the converging technological, clinical, and commercial dynamics that are redefining value propositions and adoption pathways for robotic radiotherapy
Robotic radiotherapy’s landscape is undergoing transformative shifts driven by converging forces in technology, clinical evidence, and care delivery models. Advances in image guidance, artificial intelligence–assisted treatment planning, and tighter integration with diagnostic imaging have elevated the clinical capabilities of both gantry-based and robotic arm systems, enabling more complex lesion targeting and adaptive delivery across an expanding range of indications. Concurrently, healthcare providers are recalibrating capital allocation toward technologies that demonstrably reduce treatment times and improve throughput, thereby changing procurement priorities.
Moreover, regulatory and reimbursement environments are evolving in ways that influence adoption velocity. Payers are increasingly attentive to real-world outcomes and value-based contracting, which pressures manufacturers and providers to generate post-market evidence and demonstrate economic as well as clinical value. Supply chain resilience and service model innovations are also reshaping vendor-provider relationships, as organizations seek predictable uptime and outcome-aligned service agreements. Collectively, these shifts create an environment where differentiation depends on clinical performance, seamless interoperability, and robust lifecycle support rather than on single-feature superiority alone.
Examining how tariff adjustments in the United States have reshaped supply chain resilience, procurement choices, and vendor strategies across the robotic radiotherapy ecosystem
The introduction of new tariffs in the United States in 2025 has had palpable ripple effects across the robotic radiotherapy ecosystem, altering cost structures, procurement timelines, and supply chain strategies. Manufacturers that rely on international component sourcing have had to reassess supplier relationships, accelerate regional sourcing diversification, and in some cases absorb additional cost pressures that affect pricing negotiations with health systems. Meanwhile, provider procurement teams are balancing the need for high-performance equipment against capital constraints and lifecycle service commitments, which has prompted longer lead times and more rigorous total-cost-of-ownership evaluations.
In response, vendors and purchasers are increasingly pursuing mitigation strategies that emphasize near-term resilience and long-term flexibility. These include qualifying alternative component suppliers, redesigning product architectures to reduce exposure to tariffed inputs, and negotiating service-centric commercial models that shift some value from hardware sales to outcome-linked support. Additionally, stakeholders are engaging more frequently with policymakers and industry consortia to articulate the clinical implications of tariff-induced cost inflation. Through these adaptations, the ecosystem is seeking to preserve patient access to advanced treatments while maintaining viable commercial pathways for technology providers.
Translating detailed segmentation across product architectures, component ecosystems, clinical indications, end-user profiles, and modality pathways into tailored commercial and clinical strategies
Segmentation-centric insight is essential to translate product and clinical differentiators into actionable commercial strategies. Product type differences between gantry-based systems and robotic arm-based systems drive distinct clinical workflows and facility planning considerations, as gantry platforms typically integrate with conventional linac infrastructure while robotic arms emphasize stereotactic precision and flexible beam trajectories. Component-level distinctions among hardware, services, and software necessitate tailored go-to-market approaches; hardware procurement often involves capital committees and infrastructure fit, services require long-term contracts and uptime assurances, and software opens opportunities for recurring licensing and AI-enabled clinical decision support.
Treatment application segmentation spanning brain tumors, lung cancer, prostate cancer, and spine tumors highlights modality-specific clinical requirements and evidence needs, since each indication imposes unique imaging, immobilization, and motion-management demands. End-user segmentation across ambulatory surgical centers, hospitals, and specialty cancer centers underscores divergent purchasing behaviors and operational priorities, with ambulatory sites favoring throughput and compact footprints, hospitals prioritizing integration with broader clinical services, and specialty centers emphasizing clinical differentiation and complex-case capabilities. Finally, modality segmentation between stereotactic body radiotherapy and stereotactic radiosurgery influences treatment planning complexity, fractionation paradigms, and the types of clinical data that stakeholders expect to support adoption and reimbursement decisions.
Unpacking regional adoption dynamics and infrastructure considerations that determine deployment success across the Americas, Europe Middle East and Africa, and Asia-Pacific healthcare landscapes
Regional dynamics materially influence how robotic radiotherapy technologies are adopted, deployed, and supported across health systems. In the Americas, innovation centers, integrated delivery networks, and a relatively mature reimbursement framework create fertile ground for early adoption of advanced systems, while provider groups emphasize interoperability with health IT infrastructure and evidence demonstrating patient outcome improvements. By contrast, Europe, Middle East & Africa present a heterogeneous mosaic of regulatory pathways and funding models that require nimble market access strategies and localized value dossiers tailored to national health technology assessment processes.
Asia-Pacific exhibits rapid capacity expansion in oncology services, driven by rising cancer incidence, investments in tertiary care infrastructure, and growing emphasis on specialty centers that can offer high-acuity treatments. In each region, supply chain logistics, local service network depth, and clinician training programs shape adoption velocity. Consequently, commercial strategies must align with regional reimbursement realities, clinician education imperatives, and the availability of local technical support to ensure sustained uptime and clinical confidence.
Evaluating how established manufacturers and emerging entrants are redefining competitive differentiation through integrated clinical solutions, lifecycle service models, and data-driven partnerships
Key corporate players are differentiating through integrated solution portfolios, service excellence, and investments in evidence generation. Leading technology providers are expanding capabilities across imaging-guided delivery, motion management, and automated planning to reduce clinician burden and improve treatment precision. Strategic partnerships between device manufacturers and software innovators are accelerating the development of AI-driven planning tools and adaptive delivery workflows, which in turn create new revenue streams and longer-term customer engagement opportunities.
Competitive positioning increasingly hinges on lifecycle support models that prioritize uptime, remote diagnostics, and outcome-oriented service contracts. Companies that combine deep clinical collaboration with robust post-market data collection can better demonstrate comparative clinical performance and support payer conversations. At the same time, newer entrants are seeking niches by offering specialized hardware or modular software that integrates into existing infrastructures, thereby enabling providers to enhance capabilities without replacing full systems. Together, these approaches are reshaping how vendors capture value across product, service, and software dimensions.
Prioritizing pragmatic strategic actions for providers and vendors to strengthen resilience, evidence development, and commercial models that accelerate responsible adoption
Industry leaders should prioritize a set of pragmatic actions to navigate the evolving robotic radiotherapy environment and accelerate sustainable adoption. First, aligning product roadmaps with clinician-validated use cases and investing in post-market evidence generation will strengthen value propositions and payer conversations. Second, diversifying supply chains and qualifying regional manufacturing or component sources will mitigate exposure to trade disruptions and tariff volatility while preserving price competitiveness.
Third, shifting commercial emphasis toward service and software-led revenue models can enhance customer retention and create predictable income streams that support long-term innovation. Fourth, building comprehensive training and credentialing programs for clinicians and medical physicists will lower operational barriers and shorten time-to-value for new adopters. Lastly, engaging early with payers and health technology assessment bodies to translate real-world outcomes into reimbursement narratives will accelerate uptake. Executed together, these steps help organizations balance near-term operational resilience with long-term strategic positioning.
Describing a multi-source, expert-validated research approach that integrates clinical literature, regulatory signals, and frontline stakeholder perspectives to ensure analytic rigor
The research methodology underpinning this analysis combines a structured review of peer-reviewed clinical literature, regulatory filings, and device technical specifications with qualitative interviews and expert consultations to ensure a balanced perspective. Structured synthesis of clinical studies and technology white papers informed assessments of device capabilities, clinical use cases, and treatment workflow implications. Additionally, engagement with practicing radiation oncologists, medical physicists, hospital procurement leaders, and service operations executives provided practical insights into real-world adoption barriers and success factors.
Supplementing primary inputs, the methodology incorporates trend analysis of policy and reimbursement developments, supply chain mapping to identify component dependencies, and comparative product benchmarking to highlight differentiation points. Rigorous cross-validation of findings was achieved through triangulation across evidence sources and iterative review by domain experts, ensuring that conclusions are grounded in both clinical realities and commercial dynamics.
Synthesizing critical insights that underscore the necessity of clinical evidence, service reliability, and software-enabled workflows to convert precision capabilities into consistent patient value
Robotic radiotherapy stands at a pivotal juncture where technical maturity, clinical evidence, and commercial innovation converge to create tangible opportunities for improved patient care. The conclusion synthesizes the report’s key insights: adoption is contingent not only on technical performance but also on robust service delivery models, clinician enablement, and alignment with payer expectations. As stakeholders navigate changing policy landscapes and supply chain constraints, adaptability in procurement, evidence generation, and partnership models will determine who captures long-term value.
Looking ahead, sustained investment in interoperability, software-enabled clinical workflows, and outcome measurement will be essential for translating precision capabilities into consistent patient benefits. The ecosystem’s evolution will favor organizations that couple technical excellence with operational reliability and data-driven value propositions, enabling clinicians to deliver complex, high-precision treatments with confidence and efficiency.
Note: PDF & Excel + Online Access - 1 Year
Framing the strategic and clinical rationale for robotic radiotherapy adoption by synthesizing precision performance, workflow integration, and stakeholder investment priorities
Robotic radiotherapy represents a convergence of precision engineering, advanced imaging, and adaptive clinical workflows that is reshaping radiotherapeutic practice. This report’s introduction frames the technology’s clinical imperatives, from submillimeter targeting and motion compensation to reduced treatment margins that preserve healthy tissue. It also situates robotic radiotherapy within broader oncology care trajectories, where multidisciplinary coordination, patient throughput pressures, and emerging reimbursement paradigms influence adoption decisions.
Transitioning from clinical potential to operational reality requires clarity on technology differentiation, capital and operational expenditure trade-offs, and the interoperability requirements that health systems prioritize. The introduction therefore summarizes the core technical capabilities that matter to radiation oncologists and medical physicists, outlines how device ecosystems integrate with oncology information systems and imaging modalities, and highlights adoption catalysts such as evidence demonstrating improved toxicity profiles or workflow efficiencies. Taken together, this orientation establishes the analytical lens used throughout the report to evaluate strategic choices facing manufacturers, providers, and payers.
Identifying the converging technological, clinical, and commercial dynamics that are redefining value propositions and adoption pathways for robotic radiotherapy
Robotic radiotherapy’s landscape is undergoing transformative shifts driven by converging forces in technology, clinical evidence, and care delivery models. Advances in image guidance, artificial intelligence–assisted treatment planning, and tighter integration with diagnostic imaging have elevated the clinical capabilities of both gantry-based and robotic arm systems, enabling more complex lesion targeting and adaptive delivery across an expanding range of indications. Concurrently, healthcare providers are recalibrating capital allocation toward technologies that demonstrably reduce treatment times and improve throughput, thereby changing procurement priorities.
Moreover, regulatory and reimbursement environments are evolving in ways that influence adoption velocity. Payers are increasingly attentive to real-world outcomes and value-based contracting, which pressures manufacturers and providers to generate post-market evidence and demonstrate economic as well as clinical value. Supply chain resilience and service model innovations are also reshaping vendor-provider relationships, as organizations seek predictable uptime and outcome-aligned service agreements. Collectively, these shifts create an environment where differentiation depends on clinical performance, seamless interoperability, and robust lifecycle support rather than on single-feature superiority alone.
Examining how tariff adjustments in the United States have reshaped supply chain resilience, procurement choices, and vendor strategies across the robotic radiotherapy ecosystem
The introduction of new tariffs in the United States in 2025 has had palpable ripple effects across the robotic radiotherapy ecosystem, altering cost structures, procurement timelines, and supply chain strategies. Manufacturers that rely on international component sourcing have had to reassess supplier relationships, accelerate regional sourcing diversification, and in some cases absorb additional cost pressures that affect pricing negotiations with health systems. Meanwhile, provider procurement teams are balancing the need for high-performance equipment against capital constraints and lifecycle service commitments, which has prompted longer lead times and more rigorous total-cost-of-ownership evaluations.
In response, vendors and purchasers are increasingly pursuing mitigation strategies that emphasize near-term resilience and long-term flexibility. These include qualifying alternative component suppliers, redesigning product architectures to reduce exposure to tariffed inputs, and negotiating service-centric commercial models that shift some value from hardware sales to outcome-linked support. Additionally, stakeholders are engaging more frequently with policymakers and industry consortia to articulate the clinical implications of tariff-induced cost inflation. Through these adaptations, the ecosystem is seeking to preserve patient access to advanced treatments while maintaining viable commercial pathways for technology providers.
Translating detailed segmentation across product architectures, component ecosystems, clinical indications, end-user profiles, and modality pathways into tailored commercial and clinical strategies
Segmentation-centric insight is essential to translate product and clinical differentiators into actionable commercial strategies. Product type differences between gantry-based systems and robotic arm-based systems drive distinct clinical workflows and facility planning considerations, as gantry platforms typically integrate with conventional linac infrastructure while robotic arms emphasize stereotactic precision and flexible beam trajectories. Component-level distinctions among hardware, services, and software necessitate tailored go-to-market approaches; hardware procurement often involves capital committees and infrastructure fit, services require long-term contracts and uptime assurances, and software opens opportunities for recurring licensing and AI-enabled clinical decision support.
Treatment application segmentation spanning brain tumors, lung cancer, prostate cancer, and spine tumors highlights modality-specific clinical requirements and evidence needs, since each indication imposes unique imaging, immobilization, and motion-management demands. End-user segmentation across ambulatory surgical centers, hospitals, and specialty cancer centers underscores divergent purchasing behaviors and operational priorities, with ambulatory sites favoring throughput and compact footprints, hospitals prioritizing integration with broader clinical services, and specialty centers emphasizing clinical differentiation and complex-case capabilities. Finally, modality segmentation between stereotactic body radiotherapy and stereotactic radiosurgery influences treatment planning complexity, fractionation paradigms, and the types of clinical data that stakeholders expect to support adoption and reimbursement decisions.
Unpacking regional adoption dynamics and infrastructure considerations that determine deployment success across the Americas, Europe Middle East and Africa, and Asia-Pacific healthcare landscapes
Regional dynamics materially influence how robotic radiotherapy technologies are adopted, deployed, and supported across health systems. In the Americas, innovation centers, integrated delivery networks, and a relatively mature reimbursement framework create fertile ground for early adoption of advanced systems, while provider groups emphasize interoperability with health IT infrastructure and evidence demonstrating patient outcome improvements. By contrast, Europe, Middle East & Africa present a heterogeneous mosaic of regulatory pathways and funding models that require nimble market access strategies and localized value dossiers tailored to national health technology assessment processes.
Asia-Pacific exhibits rapid capacity expansion in oncology services, driven by rising cancer incidence, investments in tertiary care infrastructure, and growing emphasis on specialty centers that can offer high-acuity treatments. In each region, supply chain logistics, local service network depth, and clinician training programs shape adoption velocity. Consequently, commercial strategies must align with regional reimbursement realities, clinician education imperatives, and the availability of local technical support to ensure sustained uptime and clinical confidence.
Evaluating how established manufacturers and emerging entrants are redefining competitive differentiation through integrated clinical solutions, lifecycle service models, and data-driven partnerships
Key corporate players are differentiating through integrated solution portfolios, service excellence, and investments in evidence generation. Leading technology providers are expanding capabilities across imaging-guided delivery, motion management, and automated planning to reduce clinician burden and improve treatment precision. Strategic partnerships between device manufacturers and software innovators are accelerating the development of AI-driven planning tools and adaptive delivery workflows, which in turn create new revenue streams and longer-term customer engagement opportunities.
Competitive positioning increasingly hinges on lifecycle support models that prioritize uptime, remote diagnostics, and outcome-oriented service contracts. Companies that combine deep clinical collaboration with robust post-market data collection can better demonstrate comparative clinical performance and support payer conversations. At the same time, newer entrants are seeking niches by offering specialized hardware or modular software that integrates into existing infrastructures, thereby enabling providers to enhance capabilities without replacing full systems. Together, these approaches are reshaping how vendors capture value across product, service, and software dimensions.
Prioritizing pragmatic strategic actions for providers and vendors to strengthen resilience, evidence development, and commercial models that accelerate responsible adoption
Industry leaders should prioritize a set of pragmatic actions to navigate the evolving robotic radiotherapy environment and accelerate sustainable adoption. First, aligning product roadmaps with clinician-validated use cases and investing in post-market evidence generation will strengthen value propositions and payer conversations. Second, diversifying supply chains and qualifying regional manufacturing or component sources will mitigate exposure to trade disruptions and tariff volatility while preserving price competitiveness.
Third, shifting commercial emphasis toward service and software-led revenue models can enhance customer retention and create predictable income streams that support long-term innovation. Fourth, building comprehensive training and credentialing programs for clinicians and medical physicists will lower operational barriers and shorten time-to-value for new adopters. Lastly, engaging early with payers and health technology assessment bodies to translate real-world outcomes into reimbursement narratives will accelerate uptake. Executed together, these steps help organizations balance near-term operational resilience with long-term strategic positioning.
Describing a multi-source, expert-validated research approach that integrates clinical literature, regulatory signals, and frontline stakeholder perspectives to ensure analytic rigor
The research methodology underpinning this analysis combines a structured review of peer-reviewed clinical literature, regulatory filings, and device technical specifications with qualitative interviews and expert consultations to ensure a balanced perspective. Structured synthesis of clinical studies and technology white papers informed assessments of device capabilities, clinical use cases, and treatment workflow implications. Additionally, engagement with practicing radiation oncologists, medical physicists, hospital procurement leaders, and service operations executives provided practical insights into real-world adoption barriers and success factors.
Supplementing primary inputs, the methodology incorporates trend analysis of policy and reimbursement developments, supply chain mapping to identify component dependencies, and comparative product benchmarking to highlight differentiation points. Rigorous cross-validation of findings was achieved through triangulation across evidence sources and iterative review by domain experts, ensuring that conclusions are grounded in both clinical realities and commercial dynamics.
Synthesizing critical insights that underscore the necessity of clinical evidence, service reliability, and software-enabled workflows to convert precision capabilities into consistent patient value
Robotic radiotherapy stands at a pivotal juncture where technical maturity, clinical evidence, and commercial innovation converge to create tangible opportunities for improved patient care. The conclusion synthesizes the report’s key insights: adoption is contingent not only on technical performance but also on robust service delivery models, clinician enablement, and alignment with payer expectations. As stakeholders navigate changing policy landscapes and supply chain constraints, adaptability in procurement, evidence generation, and partnership models will determine who captures long-term value.
Looking ahead, sustained investment in interoperability, software-enabled clinical workflows, and outcome measurement will be essential for translating precision capabilities into consistent patient benefits. The ecosystem’s evolution will favor organizations that couple technical excellence with operational reliability and data-driven value propositions, enabling clinicians to deliver complex, high-precision treatments with confidence and efficiency.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
195 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
- 2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
- 3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
- 4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Porter’s Five Forces Analysis
- 4.4. PESTLE Analysis
- 4.5. Market Outlook
- 4.5.1. Near-Term Market Outlook (0–2 Years)
- 4.5.2. Medium-Term Market Outlook (3–5 Years)
- 4.5.3. Long-Term Market Outlook (5–10 Years)
- 4.6. Go-to-Market Strategy
- 5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Robotic Radiotherapy Market, by Product Type
- 8.1. Gantry-Based Systems
- 8.2. Robotic Arm-Based Systems
- 9. Robotic Radiotherapy Market, by Component
- 9.1. Hardware
- 9.2. Services
- 9.3. Software
- 10. Robotic Radiotherapy Market, by Treatment Application
- 10.1. Brain Tumors
- 10.2. Lung Cancer
- 10.3. Prostate Cancer
- 10.4. Spine Tumors
- 11. Robotic Radiotherapy Market, by Modality
- 11.1. Stereotactic Body Radiotherapy
- 11.2. Stereotactic Radiosurgery
- 12. Robotic Radiotherapy Market, by End User
- 12.1. Ambulatory Surgical Centers
- 12.2. Hospitals
- 12.3. Specialty Cancer Centers
- 13. Robotic Radiotherapy Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Robotic Radiotherapy Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Robotic Radiotherapy Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. United States Robotic Radiotherapy Market
- 17. China Robotic Radiotherapy Market
- 18. Competitive Landscape
- 18.1. Market Concentration Analysis, 2025
- 18.1.1. Concentration Ratio (CR)
- 18.1.2. Herfindahl Hirschman Index (HHI)
- 18.2. Recent Developments & Impact Analysis, 2025
- 18.3. Product Portfolio Analysis, 2025
- 18.4. Benchmarking Analysis, 2025
- 18.5. Accuray Incorporated
- 18.6. Brainlab AG
- 18.7. C-RAD AB
- 18.8. Elekta AB
- 18.9. IBA S.A.
- 18.10. Mevion Medical Systems, Inc.
- 18.11. RaySearch Laboratories AB
- 18.12. RefleXion Medical, Inc.
- 18.13. Siemens Healthineers AG
- 18.14. ViewRay, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
